Cystatin C and interleukin‐6 for prognosticating patients with acute decompensation of cirrhosis

• DOI: 10.1002/jgh3.12516
• Publication Date: 2021-03-09T15:46:11Z
• Authors: Gaurav Padia; Bhawana Mahajan; Ajay Kumar; Ujjwal Sonika; Amol S Dahale; Sanjeev Sachdeva; Ashok Dalal; Roshan George
• Keywords: Decompensation

Systemic inflammation and organ dysfunction/failure can complicate acute decompensation (AD) of cirrhosis with progression to acute-on-chronic liver failure (ACLF), leading increased mortality. There are few studies on serum biomarkers predicting renal dysfunction (RD) or ACLF in AD. Serum cystatin C (CysC) interleukin-6 (IL-6) were evaluated for RD, ACLF, mortality AD patients.Consecutive patients seen from January 2018 June 2019 included. IL-6 CysC measured at the time index presentation. Patients followed 90 days until primary (development RD) secondary outcomes mortality). Multivariate analysis was performed find whether independently predict outcomes.A total 124 screened; 88 On follow up, 22 (27.3%) developed 11 (11/57, 19.3%) 21 (24%) died. The predicted RD (odds ratio [OR] 7.97, 95% confidence interval [CI] 2.70-23.53, P = 0.001) (OR 5.486, CI 1.456-20.6, 0.012) development. not an independent predictor (P 0.315), 0.168), 0.225).Serum development